中国肿瘤生物治疗杂志2026，Vol.33Issue(5)：477-485,9.DOI:10.3872/j.issn.1007-385x.2026.05.001
靶向树突状细胞代谢重编程:肿瘤免疫治疗新策略
Targeting dendritic cell metabolic reprogramming:a new strategy for tumor immunotherapy
摘要
Abstract
Dendritic cells(DCs)serve as the central hub connecting innate immunity and adaptive immunity,and their functional homeostasis is critical for mediating tumor immune surveillance.However,the tumor microenvironment(TME)drives metabolic reprogramming in DCs through competition for nutrients and accumulation of immunosuppressive metabolites,thereby inducing defects in antitumor immune responses.This article systematically reviews the remodeling mechanisms of DC subsets across three major metabolic dimensions in the TME:in glucose metabolism,lactate-rich microenvironments suppress MHC class Ⅱ molecule expression via GPR81 signaling,impairing the antigen-presenting capacity of conventional DCs(cDCs);in lipid metabolism,fatty acid oxidation mediated by the Wnt5a-β-catenin-PPARγ-CPT1A axis promotes the polarization of cDCs toward an immunosuppressive phenotype;and in amino acid metabolism,cascade activation of the Arg1-IDO1 pathway induces DCs to acquire a tolerogenic phenotype.In response to these metabolic abnormalities,current intervention strategies have expanded from single-target modulation to multimodal combination approaches,including lipid nanoparticle-based in situ vaccines and mRNA delivery systems,metabolic-immune synergistic blockade,and metabolically optimized DC vaccines.Therefore,deepening the understanding and targeting of DC metabolic checkpoints not only holds promise for reversing the immunosuppressive microenvironment and overcoming therapeutic resistance,but also provides important scientific rationale and translational strategies for developing next-generation metabolic-immune combination therapies.关键词
树突状细胞/代谢重编程/肿瘤微环境/免疫抑制/代谢检查点/联合疗法Key words
dendritic cell(DC)/metabolic reprogramming/tumor microenvironment(TME)/immunosuppression/metabolic checkpoint/combination therapy分类
医药卫生引用本文复制引用
任子玉,吴静,陈京涛..靶向树突状细胞代谢重编程:肿瘤免疫治疗新策略[J].中国肿瘤生物治疗杂志,2026,33(5):477-485,9.基金项目
国家自然科学基金(82471802) （82471802）
